Advertisement

Topics

Nexstim gains FDA clearance to commercialise its NBT® system in the US for the treatment of depression

09:00 EST 13 Nov 2017 | GlobalNewsWire (2014)

This article has expired, however you can still download the PDF.
Preview:
Company announcement, Helsinki, 13 November 2017 at 3 pm Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company"), a medical technology company developing and marketing pioneering navigated non-invasive brain stimulati...

Other Sources for this Article

NEXT ARTICLE

More From BioPortfolio on "Nexstim gains FDA clearance to commercialise its NBT® system in the US for the treatment of depression"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...